Edit
islandpharmaceuticals
https://www.islandpharmaceuticals.com/site/content/Last activity: 15.11.2022
Active
Island (ASX: ILA) is a mid clinical-stage research drug repurposing company, focused on the rapid development of antiviral therapeutics for infectious diseases.
We have a lead asset – ISLA-101 - that was initially developed by our wholly-owned subsidiary, Isla Pharmaceuticals. ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquitoes (or vector) borne diseases.
Dengue fever is the very definition of an unmet medical need. While 390 million humans are infected each year, it is thought that around 30-50% of people with the disease do not present with symptoms, enabling the virus to spread within communities. Warming global climates are accelerating the presence of mosquito-borne viruses that can cause death to the US, Europe and Australia
There is no specific pharmaceutical treatment and the one vaccine which exists is available to a highly restricted audience.
Island has repurposed ISLA-101, an antiviral oral drug to treat mosquito-borne viruses (eg dengue fever / Zika) and intends to complete Phase II studies with a significantly de-risked clinical program.
We have a lead asset – ISLA-101 - that was initially developed by our wholly-owned subsidiary, Isla Pharmaceuticals. ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquitoes (or vector) borne diseases.
Dengue fever is the very definition of an unmet medical need. While 390 million humans are infected each year, it is thought that around 30-50% of people with the disease do not present with symptoms, enabling the virus to spread within communities. Warming global climates are accelerating the presence of mosquito-borne viruses that can cause death to the US, Europe and Australia
There is no specific pharmaceutical treatment and the one vaccine which exists is available to a highly restricted audience.
Island has repurposed ISLA-101, an antiviral oral drug to treat mosquito-borne viruses (eg dengue fever / Zika) and intends to complete Phase II studies with a significantly de-risked clinical program.
Location: Australia, Victoria, Melbourne
Employees: 1-10
Investors 1
| Date | Name | Website |
| - | Alium Capi... | aliumcap.c... |
Mentions in press and media 5
| Date | Title | Description |
| 15.11.2022 | Island to present at World Antiviral Congress 2022 | MELBOURNE, Australia, Nov. 15, 2022 /PRNewswire/ -- Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA) is pleased to advise that CEO and Managing Director, Dr David Foster will present at... |
| 10.02.2022 | Island Pharmaceuticals : Updated Investor Presentation & Webinar Invitation | For personal use only 10 February 2022 ASX Announcement Updated investor presentation and webinar invitation MELBOURNE Australia, 10 February 2022: Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd... |
| 27.01.2022 | Island Pharmaceuticals : Quarterly Activity Report & Appendix 4C | For personal use only 27 January 2022 ASX Announcement December 2021 Quarterly Activity Report and Appendix 4C Teresa Byrne appointed Vice President Clinical Product Development Key agreements signed for Island's ISLA-101 Phase 2a dengue fe... |
| 20.10.2021 | Island Pharmaceuticals to discuss its potential dengue fever preventative at Pharma Meeting Brazil & Latam 2021 | MELBOURNE, Australia, Oct. 20, 2021 /PRNewswire/ -- Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA) is pleased to be attending Pharma Meeting Brazil & Latam 2021, this week and pre... |
| 19.05.2021 | Island Pharmaceuticals granted key patent for ISLA-101 in the United States | Island's lead asset, ISLA-101 granted key patent from United Stated Patent & Trademark Office Patent underpins Island's drug repurposing strategy to rapidly and efficiently develop antiviral therapies with a key focus being mosquito bor... |